BiotechTube

UB-612

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COVID-19

Conditions

COVID-19

Trial Timeline

Aug 5, 2021 → Oct 31, 2021

NCT ID
NCT04967742

About UB-612

UB-612 is a phase 1 stage product being developed by Vaxxinity for COVID-19. The current trial status is completed. This product is registered under clinical trial identifier NCT04967742. Target conditions include COVID-19.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (3)

NCT IDPhaseStatus
NCT04967742Phase 1Completed
NCT04683224Phase 2/3Withdrawn
NCT04545749Phase 1Completed

Competing Products

20 competing products in COVID-19

See all competitors
ProductCompanyStageHype Score
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
51
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
47
Gimsilumab + PlaceboRoivant SciencesPhase 2
49
Icosapent ethylAmarin CorporationPhase 2
44
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
77
InfliximabCelltrionPhase 2
52
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
77
Enzalutamide PillAstellas PharmaPhase 2
52
S-892216 + PlaceboShionogiPhase 2
52
S-892216 + CarbamazepineShionogiPhase 1
33
FOY-305 + PlaceboOno PharmaceuticalPhase 3
77
DesidustatZydus LifesciencesPhase 2
52
LY3819253 + PlaceboEli LillyPhase 1
33
Bamlanivimab + Etesevimab + Placebo + VIR-7831 + BebtelovimabEli LillyPhase 2
52
BamlanivimabEli LillyPhase 2
52
LY3127804 + PlaceboEli LillyPhase 2
52
Baricitinib + PlaceboEli LillyPhase 3
77
BamlanivimabEli LillyPre-clinical
23
LY3819253 + Placebo + RemdesivirEli LillyPhase 3
77
LY3819253 + LY3832479 + LY3853113 + PlaceboEli LillyPhase 2/3
65

Other Products from Vaxxinity

UB-612 + BNT162b2 vaccine + ChAdOx1-S vaccine + Sinopharm BIBPPhase 3
69
UB-612Phase 2/3
57
UB-612 + PlaceboPhase 2
44
UB-312 + PlaceboPhase 1
25
UB-612Phase 1
25